Wetzel Investment Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-780
Closed -$42.3K – 217
2024
Q2
$42.3K Hold
780
– – 0.02% 257
2024
Q1
$37.7K Hold
780
– – 0.02% 286
2023
Q4
$40K Buy
+780
New +$40.9K 0.02% 269

Other funds holding BMY

Wetzel Investment Advisors's BMY Position: Q3 2024 in Review

Wetzel Investment Advisors sold out of Bristol-Myers Squibb (BMY) in Q3 2024, closing a stake of 780 shares — an estimated $42.3K sold.

Wetzel Investment Advisors first reported a position in BMY in Q4 2023 and held it in 3 quarters. The position peaked at $42.3K in Q2 2024. 2,265 funds tracked by Wall St. Rank hold BMY as of Q3 2024.

  • Wetzel Investment Advisors reported no remaining Bristol-Myers Squibb position as of Q3 2024 after selling out during the quarter.
  • Wetzel Investment Advisors sold 780 Bristol-Myers Squibb shares in Q3 2024, an estimated $42.3K.
  • Wetzel Investment Advisors first reported a position in Bristol-Myers Squibb in Q4 2023 and held it in 3 quarters.
  • Wetzel Investment Advisors's Bristol-Myers Squibb position peaked at $42.3K in Q2 2024.
  • 2,265 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2024.

Based on Wetzel Investment Advisors's 13F filing for Q3 2024, filed 29 Oct 2024.